Home
What is
Hepatitis
How is it
Transmitted
Long Term
Prognosis
Complications of
HCV
Liver
Biopsy
Treatment Info
(Interferon, Herbal, etc)
Lab Tests (PCR,
Genotype,etc.)
Nutrition
& Alternative Info
Patient
Information (Support Groups, Doctor Listing,
etc)
Related
Webpages
Transplant
Info
HCV
Webrings
My
guestbookbook
Site
Awards
FAQ &
Disclaimers
|
FDA rejects priority review for Schering-Plough
drug
PISCATAWAY, N.J., Feb 10 (Reuters) - The U.S. Food and Drug
Administration has refused to grant priority review to
Schering-Plough Corp.'s (NYSE:SGP - news) PEG-INTRON treatment for
hepatitis C, Enzon Inc. (NasdaqNM:ENZN - news) said on Thursday.
The treatment was placed on standard review, which takes longer,
Enzon said.
PEG-INTRON is a modified form of Schering-Plough's INTRON A that
uses proprietary technology developed by Enzon.
Schering-Plough submitted its Biologics License Application to
the FDA on Dec. 23.
Under the Prescription Drug Users Fee Act, the FDA should act on
Schering-Plough's BLA within 12 months from the date of receipt.
Priority review would have taken six months.
Enzon shares were off 5 to 48-7/8 and Schering-Plough shares
were off 2-1/4 to 43-1/16, both in morning trade on the New York
Stock Exchange.
Home | What is HCV | Transmission |
Future |
Complications |
Biopsy |
Treatment
| Lab |
Nutrition |
Patient |
Links | Transplant |
Webrings |
guestbookbook |
Awards |
FAQ
|
|